mesalamine

July 13, 2017August 29, 2017

Innovate Seeks Orphan Drug Status for Pediatric Ulcerative Colitis Therapy Candidate INN-108

News, Ulcerative colitis

Innovate Biopharmaceuticals recently submitted an application to the U.S. Food and Drug Administration (FDA) seeking orphan drug designation for its potential pediatric ulcerative colitis therapy, INN-108. The FDA issues orphan drug ... Read more

June 8, 2017June 8, 2017

FDA Approves Mesalamine Delayed–Release Tablets, Generic of Lialda, for UC

News

The U.S. Food and Drug Administration (FDA) has given final approval for Zydus Cadila to market Mesalamine Delayed–Release Tablets USP, a generic version of Lialda, in the U.S. to treat ulcerative colitis (UC). The announcement follows news ... Read more

May 11, 2017

Zydus Wins Appeal in Shire’s Patent Case Over Generic Lialda for UC

News

Zydus Pharmaceuticals won a patent battle over Shire’s ulcerative colitis drug Lialda (mesalamine), with the U.S. Court of Appeals for the Federal Circuit ruling that Zydus’ proposed generic version of Lialda ... Read more

October 23, 2015October 23, 2015

IBD Drug Delivery Directly to GI Tract May Be Possible with Ultrasound

News

In a new study entitled “Ultrasound-mediated gastrointestinal drug delivery,” a team of scientists report a new method using ultrasounds to deliver, fast and efficiently, drugs to the gastrointestinal tract. This ... Read more

August 18, 2015August 18, 2015

Pentasa Caps FDA- Approved For New Administration Approach

IBD News, News

The Food and Drug Administration (FDA) recently approved a supplemental New Drug Application (sNDA) for Pentasa (melamine), updating the therapy’s path of administration. Now, the Pentasa capsules can be opened and the contents ... Read more